Overcoming Resistance in Metastatic Prostate Cancer: Repurposing Pimitespib
/in Drug repurposing, Preclinical Research/by MaxPredictive Oncology’s Breakthrough in Drug Repurposing Offers Hope for Patients
/in Drug repurposing, Preclinical Research/by MaxRepurposing FDA-Approved Drugs for PIM-1 Kinase Inhibition: A Potential Avenue for Prostate Cancer
/in Drug repurposing, Preclinical Research/by MaxProject Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 225Ac abiraterone abiraterone acetate ADC ADT ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T CD3 clinical trial crispr darolutamide docetaxel drug repurposing enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP1 PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data STEAP1 T-cell therapy
Latest Posts
- A “Plug-and-Play” CAR-T That Could Be Updated as Cancer Changes September 23, 2026
- B7-H3 May Be Doing More Than Marking Prostate Cancer September 23, 2026
- New Phase 2 trial for JNJ-101556143 aka HLD-0915 in mCRPC / mAPMR Prostate Cancer September 22, 2026
- JUR-003 Enters Phase 1 Trial in Metastatic Prostate Cancer September 22, 2026